FBC represented Bristol-Myers Squibb Company (NYSE: BMY) in connection with its $12M equity investment in Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery.
The equity offering was made as a private placement of public equity (PIPE). The equity investment is being made in conjunction with a clinical trial collaboration entered into between Bristol-Myers Squibb’s and Compugen to evaluate the safety and tolerability of Compugen’s COM701, an investigational anti-PVRIG antibody, in combination with Bristol-Myers Squibb’s programmed death-1 (PD-1) immune checkpoint inhibitor Opdivo (nivolumab), in patients with advanced solid tumors.
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
Representation of Bristol-Myers Squibb Company in its $12M Investment in Compugen Ltd.
By Raz Tepper & Sharon Rosen | Oct 2018 | Transaction
Search by
- Arbitration & Mediation
- Aviation & Maritime
- Banking & Finance
- Blockchain and Cryptocurrency
- Capital Markets
- Class Actions & Derivative Suits
- Commercial
- Competition & Antitrust
- Cybersecurity, IT & Data Protection
- East Asia Desk
- Environmental
- Family & Inheritance Law
- FinTech
- French Desk
- Global Talent Mobility & Relocation
- Hi-Tech, Technology & Venture Capital
- Hotels & Tourism
- Insolvency & Restructuring
- Intellectual Property
- Investment Funds
- Labor & Employment
- Life Sciences & Healthcare
- Liquidation & Receivership
- Litigation
- Mergers & Acquisitions
- Philanthropy
- Planning & Zoning
- Private Asset Management
- Private Equity
- Project Finance & Energy
- Real Estate
- Regulatory
- Sports Law
- Tax
- Tax - Municipal Tax
- Tech Litigation
- Telecom & Media
- White Collar